Drug, bio-affecting and body treating compositions inventions 11/07

20070274919 - Method for measuring in vivo mutation frequency at an endogenous gene locus: The present invention relates a method for the enumeration of in vivo gene mutation. The method utilizes differential staining of GPI-anchor deficient erythrocyte populations to distinguish between wild-type and pig-a gene mutants. Quantitative analyses can be conducted on erythrocytes and/or reticulocytes, and is based upon fluorescent emission and light scatter... Agent: Nixon Peabody LLP - Patent Group

20070274924 - Spinosyn fumigants: Methods of controlling arthropod pests by dispersing spinosyn compositions in the form of aerosols, fogs, smokes, or vapors are disclosed.... Agent: Dow Agrosciences LLC

20070274925 - Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists: Compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided. The compositions provided herein are nebulizable compositions comprising quaternary ammonium muscarinic receptor antagonists. The compositions are suitable for direct administration to a patient in need thereof via a nebulizer. Also provided are... Agent: Lucas & Mercanti, LLP

20070274927 - Adherent polyol troche: A slow-dissolving troche with polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum, or a lollipop or child's pacifier. Consumers are instructed to use the troches at the end of each day and after each meal, at least... Agent: Graybeal, Jackson, Haley LLP

20070274939 - Color cosmetic compositions: A color cosmetic composition comprising at least one silicone film forming polymer, at least one pigment, and at least one dispersant that aids in dispersion of the pigment and silicone film forming polymer in the composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070274944 - Antimicrobial composition of 3-iodo-2-propynylbutyl carbamate and 1,3-butylene glycol as solvent: An antimicrobial composition of 3-iodo-2-propynylbutyl carbamate (IPBC) and 1,3-butylene glycol (BG) as solvent, in a defined weight ratio, preferably 9-11% IPBC and 89-91% BG, and personal care formulations including the composition in an amount of about 0.1-0.2% therein, at a pH of 4-9, is described.... Agent: International Specialty Products Attn: William J. Davis, Esq.

20070274945 - High molecular weight chelation structure: A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone... Agent: Schmeiser, Olsen & Watts

20070274967 - Compositions and methods of treating burn victims using stem cells: The present disclosure relates to a method for treating severe burns using a preparation of tissue-derived material, which may comprise stem cells. The method may include systemic administration of stem cells. The method may also include administration of topical preparations of stem cells or tissue extract.... Agent: Calvin Cao

20070274968 - Substrate for cell culture: An object of the present invention is to provide a means capable of transferring a cell sheet, a cell pattern or the like to a desired material at a high speed. The present invention provides a substrate for cell culture comprising a base and a cell adhesive region formed on... Agent: Sughrue Mion, PLLC

20070274907 - Magnetically targetable mitomycin c compositions and methods of their use: The present embodiments are directed to compositions and methods of delivering the compositions that comprise mitomycin C and superior magnetically targetable carrier particles. As the compositions are magnetically targetable, their use allows the localization of mitomycin C to particular locations within a patient. This allows for an increase in the... Agent: The Mccallum Law Firm, P. C.

20070274908 - Methods and compositions related to adenoassociated virus-phage particles: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic... Agent: Fulbright & Jaworski L.L.P.

20070274909 - Radiation therapy and medical imaging using uv emitting nanoparticles: The invention relates to UV emitting nanoparticles for radiation therapy purposes. If the nanoparticles are brought indirectly or directly to the diseased tissue, excitation with high energy radiation leads to VUV or UV-C emission. This UV radiation is absorbed by the surrounding organic matrix, resulting in decomposition of the material.... Agent: Philips Intellectual Property & Standards

20070274910 - A1 adenosine receptor antagonists: This invention relates to compounds of formula (I): wherein R1 is a branched or straight chain C1-C6 alkyl; R2 is of the formula (II), wherein n is an integer ranging from 1 to 8; R5 is H or (CH2)pCH3, and R6 is H or (CH2)mOH, wherein p is an integer... Agent: Alston & Bird LLP

20070274911 - Production of 2-18f-2-deoxy-d-glucose via solid-phase synthesis: The invention relates to a compound of formula (1): wherein P1,P2,P3, and P4 are each independently hydrogen or a protecting group; and n is an integer of from 2 to 20 and to the use of such compounds for the synthesis of 18F—FDG.... Agent: Ge Healthcare, Inc.

20070274912 - Histone modifications as binary switches controlling gene expression: The present invention relates to a method of modulating a chromatin binding protein or complex which binds to a functional group on an amino acid of a histone. This method involves phosphorylating or dephosphorylating a serine or threonine on the histone proximate to the amino acid under conditions effective to... Agent: Nixon Peabody LLP - Patent Group

20070274913 - Preventives/remedies for stress urinary incontinence and method of screening the same: An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070274921 - Diagnostics and therapeutics for ocular disorders: The invention relates to methods for treating, preventing and diagnosing drusen-associated disorders.... Agent: Townsend And Townsend And Crew, LLP

20070274918 - Lingo-1 structure: This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.... Agent: Fish & Richardson P.C.

20070274916 - Method for identifying compounds that affect expression of tryptophan hydroxylase isoform 2: A method for identifying analytes which directly or indirectly affect tryptophan hydroxylase isoform 2 (TPH2) expression is described. The method enables glucocorticoid receptor modulators and &bgr;-hydroxysteroid dehydrogenase type 1 (&bgr,-HSD1) inhibitors to be screened for central nervous system penetrance and activity by determining their ability to regulate expression of TPH2.... Agent: Merck And Co., Inc

20070274920 - Method for inducing a psychotic state in an animal and a high throughput assay method for identifying a candidate agent having anti-psychotic properties: A high throughput neurophysiological assay for identifying anti-psychotic compounds is disclosed. In particular, a high throughput neurophysiological assay using information obtained from injecting a neural activity blocker, such as tetrodotoxin (TTX), into one hippocampus persistently coactivated pyramidal cells in the uninjected hippocampus that initially discharged independently. In accord with the... Agent: Dilworth & Barrese, LLP

20070274915 - Modulation of anergy and methods for isolating anergy-modulating compounds: The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.... Agent: Fish & Richardson PC

20070274914 - Mptens as modifiers of the pten/igf pathway and methods of use: Human MPTEN genes are identified as modulators of the PTEN/IGF pathway, and thus are therapeutic targets for disorders associated with defective PTEN/IGF function. Methods for identifying modulators of PTEN/IGF, comprising screening for agents that modulate the activity of MPTEN are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070274917 - Pharmacologic method of lowering cholesterol production: The present invention provides a screening method for identifying test agents that modulate cell membrane cholesterol activity. The modulating activity of the test agents may be measured using lytic compounds, which cause cell lysis or increases in cell permeability in response to cell membrane cholesterol levels. The invention further provides... Agent: Foley & Lardner LLP

20070274923 - Non-invasive real-time in vivo bioluminescence imaging of local ca2+ dynamics in living organisms: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274922 - Water soluble boronic acid fluorescent reporter compounds and methods of use thereof: Described herein are boronic acid fluorescent compounds and methods of use thereof.... Agent: Gardner Groff Greenwald & Villanueva. PC

20070274926 - Method of inhibiting the transmission of viruses: A method of imparting a rapid and a persistent antiviral activity against viral-mediated diseases is disclosed. The method includes applying an antimicrobial compositions containing (a) a disinfecting alcohol, (b) an organic acid, and (c) water, and having a pH of about 5 or less, to at least one of the... Agent: Marshall, Gerstein & Borun LLP (dial)

20070274928 - Novel cyclic oxygenated compounds having cooling, fragrance, and flavor properties, and uses thereof: Compositions that include compounds capable of producing a cooling sensory effect such as certain hydroxy-ketones and hydroxy-aldehyde compounds, their cyclic semi-ketals and semiacetals, and other derivatives thereof. The compounds impart a refreshing and cooling sensation of long duration and high potency, and thus are useful in a variety of formulations,... Agent: Fish & Richardson P.C.

20070274929 - Oral composition comprising chlorhexidine and maltitol or erythritol or a mixture thereof: An oral hygiene composition comprising chlorhexidine is described which has reduced bitterness.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070274930 - Particulate flavoring composition: The present invention relates to particulate compositions comprising controlled release particles wherein discrete elements of flavouring-containing fat are dispersed in a gelatine matrix, said particles containing: 0.1 -40 wt %, preferably 5-30 wt % of flavouring; 10 -70 wt %, preferably 20 -50 wt % of gelatine; and 0.1-1.75 wt... Agent: Abelman, Frayne & Schwab

20070274933 - Amino- and hydroxysubstituted triphenyl-s-triazines as stabilizers: e

20070274931 - Long lasting waterproof sunscreen comprising metal oxide and peptide conditioner: The disclosure provides a sunscreen formulation comprising a peptide-based metal oxide sunscreen agent, such as titanium dioxide nanoparticles, and a fluid vehicle.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070274932 - Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers: The present invention relates to water in oil emulsion compositions suitable for use as sunscreen comprising: from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the emulsifying crosslinked siloxane elastomer; from about 0.01% to about 5% of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070274934 - Bis-urea compounds and compositions and method of cosmetic treatment: Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, a fatty phase and at least one compound chosen from compounds of formula (I), salts thereof, and isomers thereof, used to texture the fatty phase. Also disclosed herein is a method for texturing a cosmetic and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274935 - Method for treatment of onychomycosis: Onychomycosis present in a nail is treated by debridement such as grinding a portion of the nail, which includes an infected portion and thereafter applying a composition containing alkyl cyanoacrylate to the debrided surface which cures to a hard layer. The hard layer can be successively ground and coated with... Agent: Ralph D Chabot

20070274938 - Changing skin-color perception using quantum and optical principles in cosmetic preparations: The present invention teaches how to change the skin color perception, mainly the facial color from red, blue or yellow to white appearance, using quantum and optical principles. By selecting the right size and material of particles compounded in cosmetic preparations and applying the preparations to the skin, the scattering... Agent: Lackenbach Siegel, LLP

20070274936 - Oligonucleotide and the use thereof for modulating an isoform c beta-1 protein-kinase in the form of a skin depigmentation agent: This invention relates to oligonucleotide sequences and their derivatives. These oligonucleotide sequences are capable of hybridising with the genes or with products of the genes coding for the PKC-beta 1. This invention also relates to the use of these oligonucleotide sequences as a depigmenting or bleaching agent for the skin... Agent: Blakely, Sokoloff, Taylor & Zafman

20070274937 - Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition: A composition and method for whitening and/or depigmenting skin with a protein hydrolysate from plants belonging to the crucifer family.... Agent: Young & Thompson

20070274940 - Method of enhancing the control of viruses on skin: A method of imparting a rapid antiviral effectiveness, and a persistent antiviral effectiveness, to an animate surface is disclosed. The method includes first treating the animate surface with a preconditioning composition, followed by treating the animate surface with an antiviral composition.... Agent: Marshall, Gerstein & Borun LLP (dial)

20070274941 - Two-coat cosmetic product comprising at least one silicone polymer: The present disclosure relates to a cosmetic product comprising at least one first and at least one second compositions, wherein the at least one first composition comprises a silicone polymer of formula (I) and the at least one second composition comprises a cosmetically acceptable medium. The present disclosure also relates... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274942 - Aqueous composition comprising a polyionic dendritic polymer and an ionic surface-active agent: The invention relates to a composition comprising a single-phase aqueous phase consisting of a system containing: water; a water-dispersible or water-soluble polyionic dendritic polymer (a); at least one ionic surface active agent (b); and, optionally, a polycationic or polyanionic polymer (c) which is different from the dendritic polymer. The inventive... Agent: Jean-louis Seugnet Rhodia Inc.

20070274943 - Emulsified composition for hair: An emulsified composition for hair, which contains a nonionic surfactant that is a solid at normal temperature and has a Krafft point of at least 40° C., an oil component, and water, and which has an average emulsified particle size of 0.5 μm or less, provides long-lasting luster. Further, an... Agent: Snider & Associates

20070274947 - Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer: The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R1 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.... Agent: Ivor R. Elrifi, Ph.d. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, PC

20070274949 - Cd25 dna vaccines for treating and preventing t-cell mediated diseases: Compositions comprising nucleic acids encoding the α chain of IL-2 receptor (IL-2Ra, CD25), homologs and fragment thereof, are effective in the treatment and prevention of T cell mediated pathologies. Methods are provided for enhancing anti-ergotypic T cell activity in a subject in need thereof, and for treating or preventing T... Agent: Heslin Rothenberg Farley & Mesiti PC

20070274948 - Methods of therapy for chronic lymphocytic leukemia: Methods for treating a human with chronic lymphocytic leukemia using a combination of an interleukin-2 and an anti-CD52 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing an IL-2, the other containing an anti-CD2 antibody, according to a dosing regiment. Administering of these two... Agent: Davis Wright Tremaine 2600 Century Square

20070274946 - Tolerance to graft prior to thymic reactivation: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue, and/or cells, by disrupting sex steroid signaling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070274951 - Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070274950 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070274954 - Cloning b and t lymphocytes: This invention includes methods for producing non-human mammals expressing monoclonal or oligoclonal B or T lymphocytes, as well as embryonic and hematopoietic stem cells that differentiate into monoclonal or oligoclonal B or T cells, using cloning by nuclear transfer with a B or T cell of interest as the nuclear... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070274952 - Compositions and methods for modifying the content of polyunsaturated fatty acids in biological cells: The present invention features compositions (e.g., nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of... Agent: Ewards Angell Palmer & Dodge LLP

20070274953 - Photochemical internalization for delivery of molecules into the cytosol: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the... Agent: Cantor Colburn, LLP

20070274969 - Immortalization of mammalian cells: Genomic instability in T-antigen expressing cells can be overcome by modifying the gene expressing T-antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T-antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274972 - Maize antifungal rnase ne homolog gene sequence encoding an antimicrobial protein useful for enhancing plant resistance to pathogens: Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include novel amino acid sequences, and variants and fragments thereof, for antipathogenic polypeptides that were isolated from maize. Nucleic acid molecules comprising nucleotide sequences that encode the antipathogenic polypeptides of the embodiments are... Agent: Pioneer Hi-bred International, Inc.

20070274971 - Method of proliferating precursor cells: There is provided a method of proliferating precursor cells by modulating the expression of the protein FRS3 within the precursor cells. The method is useful for the production of large populations of precursor cells, which are useful for in vitro research techniques, including drug screening, and for in vivo therapeutic... Agent: Clark & Elbing LLP

20070274970 - Stem cells: The present invention relates to an isolated stem cell population wherein said stem cells are CD34+, capable of self regeneration, capable of differentiation into ectodermal, mesodermal and endodermal cells and capable of adhering to tissue-culture grade plastic as well as to methods of isolation of said cells, methods of culturing... Agent: Knobbe Martens Olson & Bear LLP

20070274955 - Novel galactooligosaccharide composition and the preparation thereof: Novel strains of Bifidobacterium hifidum capable of producing a novel galactosidase enzyme activity that converts lactose to a novel mixture of galactooligosaccharides. The mixture of oligosaccharidcs may be incorporated into numerous food products or animal feeds for improving gut health by promoting the growth of bifidobacteria in the gut, and... Agent: Christie, Parker & Hale, LLP

20070274975 - Method for controlling harmful organisms in bt maize crops: Method for controlling harmful organisms in genetically modified maize plants containing a gene derived from Bacillus thuringiensis, said gene encoding and expressing protein with an insecticidal action, wherein an insecticidally active quantity of one or more compounds from the groups (a) to (f) specified in detail in the description is... Agent: Buchanan, Ingersoll & Rooney PC

20070274973 - Method of controlling fungal pathogens, and agents useful for same: A method of preventing or treating infection by a range of fungal pathogens in an animal or plant or stored plant product comprising administering an effective amount of a sugar acid, in particular mannonic acid, gluconic acid or galacturonic. The sugar acid can be delivered by a biocontrol that can... Agent: Fish & Richardson PC

20070274956 - Plant germination inhibitor and method of use thereof: A novel plant germination inhibitor that without any hazardous effects on cultivated crop and without the danger of environmental pollution, can exert high efficacy with an extremely small dosage. There is provided a plant germination inhibitor comprising as an active ingredient a pigment produced in woody parts by fungi of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070274957 - Antisense antiviral compound and method for treating arenavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Arenavirus infection in a mammal. The antisense antiviral compounds are... Agent: Perkins Coie LLP

20070274964 - Cell population of nurr1-positive neuron stem cell and pharmaceutical composition thereof: The present invention relates to a population of Nurr1-positive neuron stem cells, a pharmaceutical composition including the population of Nurr1-positive neuron stem cells, and methods for isolation, culture and preservation of the Nurr1-positive neuron stem cells. More specifically, the present invention provides a method of isolation of Nurr1-positive neuron stem... Agent: Edwards Angell Palmer & Dodge LLP

20070274961 - Composition and methods for cell culturing and tissue culture platforms: This present invention describes a method of coating a polymer surface with diamond-like carbon (DLC) to render it useful as a carrier for cells derived from neural crest origin, preferable neuronal cells that form dendrites. The biopolymer to be coated with the DLC will include biodegradable polymers and other implantable... Agent: Jacobson Holman PLLC

20070274959 - In vitro method for the diagnosis of cardiovascular functionality of bone marrow-precursor cells (bmp) and/or circulation precursor cells derived from blood (bdp): The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274965 - Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates: The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34+, ALDHbr and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070274962 - Methods and composition for transplantation of dopaminergic neurons for parkinson's disease: This invention discloses methods to attach and grow a monolayer of cultured human retinal pigment epithelial cells (RPE) for use in implantation into the brain as a treatment for Parkinson's disease. The invention will enable the delivery of the transplanted RPE cells in microcarriers composed of intergratable or degradable substrates,... Agent: Jacobson Holman PLLC

20070274963 - Methods for culturing keratinocytes from human embryonic stem cells: The invention relates to methods for isolating and culturing human keratinocytes from embryonic stem cells. The methods are useful for producing substantially pure cultures of keratinocytes.... Agent: Wolf Greenfield & Sacks, P.C.

20070274960 - Methods of preparing and using novel stem cell compositions and kits comprising the same: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of... Agent: Seed Intellectual Property Law Group PLLC

20070274966 - Neural regeneration with transplanted ac133 positive cells: We focused attention on AC133 positive cells as a cell source. AC133 positive cells were transplanted to an injured sciatic nerve model and an injured spinal cord model and were found to have very intensive neural regeneration ability. Such AC133 positive cells are easily available from the peripheral blood with... Agent: Kratz, Quintos & Hanson, LLP

20070274958 - Postnatal stem cells and uses thereof: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous... Agent: Schwegman, Lundberg & Woessner/nih

20070274974 - Compositions and methods for restoring immune responsiveness in patients with immunological defects: The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface... Agent: Seed Intellectual Property Law Group PLLC

20070274976 - Ethanol dependence of alpha1 antitrypsin c-terminal lys truncation by basic carboxypeptidases: The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.... Agent: Baxter Healthcare Corporation

20070274978 - Method of killing spores: A method for killing or inactivating spores, by contacting the spores with a haloperoxidase, a source of hydrogen peroxide and a source of iodide ions. The spores may additionally be contaced with a haloperoxidase enhancing agent.... Agent: Novozymes North America, Inc.

20070274977 - Methods for lowering elevated uric acid levels using intravenous injections of peg-uricase: A method for lowering elevated uric acid levels in patients is disclosed and consists of administering to the patients an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070274979 - Compositions and methods for promoting neuronal outgrowth: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.... Agent: Pepper Hamilton LLP

20070274980 - Compositions of less immunogenic and long-circulating protein-lipid complexes: Provided are lipidic particles comprising phopatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration... Agent: Hodgson Russ LLP The Guaranty Building

20070274982 - Anti-epcam immunoglobulins: The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the... Agent: Fulbright & Jaworski L.L.P.

20070274981 - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4... Agent: Kenyon & Kenyon LLP

20070274983 - Nutritional composition comprising immunoglobulins and oligosaccharides: The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.... Agent: Foley And Lardner LLP Suite 500

20070274984 - Methods for treating autoimmune diseases using a taci-ig fusion molecule: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or... Agent: Howrey LLP

20070274985 - Antibody: The present invention refers to synthetic antibody molecules which comprise domains from naturally occuring antibodies, e.g. domains derivable from IgG, preferably of human origin, in a novel arrangement. Single chain molecules are provided which are suitable for expression in micro-organisms in their active conformation, which single chain molecules generally comprise... Agent: William Collard Collard & Roe, P.C.

20070274986 - Compositions comprising anti-ccr5 antibody: This invention provides a composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier. This invention... Agent: John P. White Cooper & Dunham LLP

20070274987 - Expression of the cysteine protease legumain in vascular and inflammatory diseases: The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists... Agent: Fitzpatrick Cella (wyeth)

20070274988 - Kiaa0779, splice variants thereof, and methods of their use: The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic, and therapeutic applications. The compositions and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274989 - Methods and compositions for the prevention and treatment of sepsis: The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that... Agent: Cheryl A Liljestrand Tanox Inc

20070274990 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Novartis Vaccines And Diagnostics Inc.

20070274991 - Treatment of tumors expressing mutant egf receptors: The invention discloses methods of treatment of tumors that express oncogenic forms of the epidermal growth factor receptor (EGFR), such as EGFRvIII. The methods include testing of cancer patients for expression of EGFRvIII in their tumors, followed by treatment with a protein that contains antibody variable regions that recognize specific... Agent: Clark & Elbing LLP

20070274993 - Immunocompetent cell activation inhibitor and use thereof: The invention relates to an immunocompetent cell activation inhibitor comprising an antibody against OPN or peptide fragment thereof; a therapeutic agent for diseases attributed to immunocompetent cell activation comprising this inhibitor as an active ingredient; and a method of treatment with the use of the therapeutic agent. The invention provides... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070274992 - Secreted protein family: This invention relates to a new family of secreted proteins, termed the SECFAM3 family, its family members including the novel human proteins INSP123, INSP124, and INSP125, herein identified as secreted proteins containing a von Willebrand Factor type C (vWFC) domain, and to the use to these proteins and nucleic acid... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274994 - Virulence-associated adhesins: Virulence-associated antigens involved in adhesin have been identified in several organisms: Haemophilus influenzae biogroup aegyptius; Escherichia coli K1; EHEC E.coli; Actinobacillus actinomycetencomitans; Haemophilus somnus; Haemophilus ducreyi; EPEC E.coli; EA EC E.coli; uropathogenic E.coli; Shigella flexneri; Brucella melitensis; Brucella suis; Ralstonia solanacearum; Sinorhizobium meliloti; Bradorhizobium japonicum; and Burkholderia fungorum. Although the... Agent: Novartis Vaccines And Diagnostics Inc.

20070274995 - Cardiotrophin-1 compositions and methods for the treatment of tumor: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of... Agent: Genentech, Inc.

20070274996 - Antibodies that bind interleukin-4 receptor: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4... Agent: Immunex Corporation Law Department

20070274997 - Compositions and methods for herpes simplex prophylaxis and treatment: The present invention concerns compositions and methods involving polypeptides, such as single chain antibodies, that target microbial antigens. Embodiments of the invention include compositions and methods related to a prophylactic and therapeutic treatments for microbes that can be neutralized prior to infection of a cell. In particular embodiments, microbes against... Agent: Fulbright & Jaworski L.L.P.

20070274998 - Novel bispecific molecules for use in therapy and diagnosis: Provided are bispecific molecules that are characterized by having at least a first binding domain which binds T-cell immune response cDNA 7 (TIRC7) and a second binding domain which binds T cell receptor (TCR), in particular TCR beta or gamma chain. Furthermore, compositions comprising said bispecific molecules and their use... Agent: John P White Cooper & Dunham

20070274999 - Method of treating disorders using platelet glycoprotein ib alpha fusion polypeptides: The present invention provides compositions and methods for treating or preventing thrombotic thrombocytopenic purpura, infective endocarditis, metastatic cancer, and sickle cell anemia disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275001 - Rational design and engineering of proteins and peptides for immunomodulation: The present invention discloses an immunomodulatory protein or peptide mimetic and method for treatment of immunosuppressive diseases and conditions by administering an effective dose of the immunoactive form of the mimetic sufficient to activate phagocytic cells and triggering phagocytosis, thereby activating the immune system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275000 - Tick engorgement factor proteins: The invention provides for novel polynucleotides and associated peptides providing tick Engorgement Factor activity and methods for using same for vaccines, thereby decreasing transmission of tick-borne disease and tick-borne pathogens.... Agent: Craig K. Sherburne

20070275003 - Human papillomavirus polypeptides and immunogenic compositions: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides... Agent: Wyeth C/o Darby & Darby, P.C.

20070275002 - Use of proteins and peptides encoded by the genome of a novel sars-associated coronavirus strain: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275004 - Group b streptococcus antigens: The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B streptococcus (GBS), also called Streptococcus Agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection.... Agent: Seed Intellectual Property Law Group PLLC

20070275006 - Iridoid glycoside composition: The present invention also relates to the method of producing the iridoid glycoside adjuvant and the products utilizing such adjuvants for induction of cellular immunity. The adjuvants may be used alone or with specific antigens. The two antigens used in the study represents HBsAg, a recombinant antigen expressed in Pichia... Agent: Fenwick & West LLP

20070275005 - Use of lipopeptides for activating t lymphocytes through the skin: The present invention relates to the use of a method of treating or preventing a disease selected from the group of skin and diseases of the mucosa, comprising administering topically to a mammal in need of such a treatment a topical medicinal product comprising a lipopeptide or a mixture thereof,... Agent: Foley And Lardner LLP Suite 500

20070275007 - Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer: Carbohydrate antigen-nanoparticle conjugates are disclosed. Methods of making carbohydrate antigen-nanoparticle conjugates are also disclosed. The carbohydrate antigen-nanoparticle conjugates can be used to inhibit metastasis of tumor cells in mammals.... Agent: Woodcock Washburn LLP

20070275008 - Synergistic diabetic phyto-nutraceutical composition: Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20070275009 - Dry fertilizer with growth hormone-containing formulation and methods of use and making: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can be incorporated into a dry fertilizer for application using the fertilizer itself or a component of the fertilizer such as one or more of the fillers commonly used in fertilizers.... Agent: Clark & Brody

20070275010 - Mva vaccines: Recombinant modified vaccinia Ankara vectors are provided having a null mutation in a gene necessary for replication of the recombinant modified vaccinia Ankara virus and at least one heterologous antigen. The disclosed vectors optionally encode at least one pro-apoptotic factor, at least one anti-apoptotic factor, at least one immunomodulator, and... Agent: Thomas, Kayden, Horstemeyer & Risley

20070275011 - Inducible bacterial expression system utilising sspa promoter from salmonella: The invention provides a new stringent starvation protein Salmonella sspA promoter and expression system suitable for expression of heterologous nucleic acids and proteins. The invention also relates to the use of an expression construct comprising either a Salmonella or an E. coli sspA promoter, or a bacterium into which the... Agent: Hoffmann & Baron, LLP

20070275012 - Pharmaceutical compositions for therapeutic use: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the... Agent: Hoffmann & Baron, LLP

20070275013 - Vaccine and method of use: A therapeutic vaccine is prepared by a method which includes the steps of extracting, with a lipid-extracting solvent, a biological fluid obtained from a person or animal infected with a lipid-containing infectious organism, the biological fluid containing the lipid-containing infectious organism, and the extraction producing an aqueous phase and a... Agent: Thomas Moga Butzel Long

20070275014 - Influenza antigens, vaccine compositions, and related methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.... Agent: Choate, Hall & Stewart LLP

20070275015 - West nile virus vaccine: The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.... Agent: Clark & Elbing LLP

20070275016 - Kennel cough vaccine: Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior... Agent: Hovey Williams LLP

20070275017 - Identification of antigenically important neisseria antigens by screening insertional mutant libraries with antiserum: A method for identifying a polypeptide of a microorganism which polypeptide is associated with an immune response in an animal which has been subjected to the microorganism, the method comprising the steps of (1) providing a plurality of different mutants of the microorganism; (2) contacting the plurality of mutant microorganisms... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275018 - Use of the gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis: The invention relates to gene NcSAG4, the RNA messenger of said gene, the oligonucleotides designed based on the nucleotide sequence thereof or any of the fragments of same, and to protein NcSAG4 encoded thereby, or any of the recombinant forms of same, expression vectors, and host cells containing same, for... Agent: Knobbe Martens Olson & Bear LLP

20070275019 - Vaccines directed to cancer-associated carbohydrate antigens: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate... Agent: Bell, Boyd & Lloyd, LLP

20070275022 - Cosmetic hair preparation: One or more esters selected among an ester of a C2-10 fatty acid with a polyhydric alcohol, an ester of a monobasic hydroxy acid with a mono- or polyhydric alcohol, and an ester of a polybasic acid with a mono- or polyhydric alcohol are incorporated into a cosmetic hair preparation... Agent: Birch Stewart Kolasch & Birch

20070275020 - Method for hair treatment with shape memory polymers: A method for producing a retrievable hairstyling using shape memory polymers is described. Here a composition is applied to the hair, said composition containing a shape memory polymer P or a macromer M that can be cross-linked to a shape memory polymer, the hair is arranged into a given (permanent)... Agent: Seed Intellectual Property Law Group PLLC

20070275021 - New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same: The present invention involves new cosmetic, personal care, cleaning agent, biocidal agent, functional food, and nutritional supplement compositions. These new compositions incorporate bioactive glass into cosmetics, personal care items, cleaning agents, biocidal agents, functional foods, and nutritional supplements. The present invention also involves methods of making and methods of using... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070275023 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070275024 - Starch films and uses thereof: The invention provides novel starch films and processes for production thereof based on starch from C-type starch granules (e.g. from legumes) and polyols (e.g. glycerol). In other aspects the invention provides wound dressings and systems for controlling microorganisms using starch films.... Agent: Michael Best & Friedrich LLP

20070275025 - Combustible mosquito coil or stick: A combustible coil or stick for controlling mosquitoes is disclosed containing an insecticidally effective amount of bifenthrin.... Agent: Merchant & Gould PC

20070275030 - Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations: The invention relates to cross-link-resistant injectable hydrogel formulations and methods of partially or practically wholly inhibiting injectable hydrogel formulations from cross-linking, for example, during irradiation, using anti-cross-linking agents, which facilitates injectability of the hydrogel formulation. The invention also relates to methods of making the cross-link-resistant, for example, irradiation cross-link resistant,... Agent: Proskauer Rose LLP

20070275031 - Implantable polymeric device for sustained release of buprenorphine with minimal initial burst: The present invention provides compositions, methods, and kits for treatment of pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time, and exhibits minimal initial burst upon subcutaneous implantation. Buprenorphine is released through pores that open to... Agent: Morrison & Foerster LLP

20070275028 - Injectable fibrin composition for bone augmentation: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.... Agent: Baxter Healthcare Corporation

20070275027 - Microparticle containing matrices for drug delivery: Polymeric matrices including microparticles that provide sustained release of a hydrophilic bioactive agent are described. The matrices can be in the form of a coating on the surface of an implantable medical article or an in situ formed matrix. The microparticles of the matrix include a first polymer and a... Agent: Kagan Binder, PLLC

20070275029 - Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders: The present invention is directed to combination therapies and drug delivery devices comprising antisense oligonucleotides directed to a raf gene. In certain embodiments, the combination therapies and drug delivery devices of the present invention are used to treat cancers and ocular diseases.... Agent: Seed Intellectual Property Law Group PLLC

20070275026 - Therapeutic use of a growth factor, nsg33: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275033 - Biodegradable polyurethane and polyurethane ureas: This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating.... Agent: Needle & Rosenberg, P.C.

20070275034 - Swellable fiber- and microfiber-forming polyether-esters and applications thereof: Biomedical and tissue engineering devices, such as surgical sutures and microporous scaffolds, respectively, which undergo swelling and increase in dimensions when placed in aqueous environments such as living tissues, are produced by the melt-spinning or electrostatic spinning into strong monofilament and multifilament yarns or microfibrous fabrics, respectively. Such devices are... Agent: Leigh P. Gregory

20070275032 - Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro: A mixture of one or several substances from group A) lubricin, proteoglycan 4 (PRG4) and phosphollipid (SAPL); with one or several substances from group B) hyaluronic acid, glycosaminoglycan and derivatives of said substances; dissolved in a solvent, used for the production of an agent for treating defective or degenerated cartilage... Agent: Jones Day

20070275035 - Minimally invasive medical implant devices for controlled drug delivery: Implantable medical devices and methods of use are provided for controlled drug delivery. The devices may include an elongated body dimensioned to facilitate minimally invasive and complete implantation into a patient, wherein the elongated body portion comprises a first, closed end portion, a second closed end portion and an intermediate... Agent: Sutherland Asbill & Brennan LLP

20070275036 - Avian follistatin product: Described herein are avian follistatin products, and methods for producing such products, in which such products are effective for a variety of conditions, including increasing muscle mass. Avian follistatin products described herein are packaged as dietary supplements or nutritional supplements are useful in muscle regeneration.... Agent: Wilson Sonsini Goodrich & Rosati

20070275038 - Food and feed compositions including resistant starch: The invention described in this application relates to a method of increasing the amount of weight gained by the mammal during a feeding period, to a method of increasing the amount of milk replacer consumed by the mammal during a feeding period, to a method of decreasing the amount of... Agent: Marshall, Gerstein & Borun LLP

20070275037 - Recombinant vitellogenin enriched feed: The invention provides an expression vector for expression of recombinant vitellogenin in an eukaryotic host. An eukaryotic host, including yeast comprising the expression vector according to the invention may be used as a feed or feed additive for both oviparous and non-oviparous animals, including domesticated animals. A transgenic yeast according... Agent: Townsend And Townsend And Crew, LLP

20070275039 - Compressed articles with microencapsulation: Microencapsulated materials are added to compressed products. Microencapsulation permits a wide range of products to be incorporated into these compressed products while maintaining the dry, compressed nature of the products. In one aspect, methods are provided that comprise forming the article, that comprises paper or fabric, in a size of... Agent: Glen M. Diehl Diehl Servilla LLC

20070275040 - Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the... Agent: Perkins Coie LLP

20070275041 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070275042 - Curable hydrophilic compositions: A curable composition is described, including a gel material derived from the curable composition, and medical articles including such material, wherein the transparent gel material includes a polymerized monofunctional poly(alkylene oxide) macromonomer component and a surface modified nanoparticle component.... Agent: 3m Innovative Properties Company

20070275043 - Wound dressings: A wound dressing comprises a wound contacting material incorporating a therapeutically effective amount of a particulate, water insoluble, inorganic silver salt containing at least 50% by weight (based on the weight of the salt) of silver for delivering silver to a wound. The preferred water-soluble, inorganic silver salt is sodium... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070275044 - Novel drug delivery technology: The invention relates to a novel drug delivery technology. More particularly the invention relates to a method of delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient; to a throwaway or reusable device for delivering at least one therapeutic compound... Agent: Dickinson Wright, PLLC

20070275045 - Composition for the treatment of warts and molluscum contagiosum: The present invention provides compositions comprising mixtures of papain and bromelain, combined with a pharmaceutically acceptable carrier, for treating viral-induced skin lesions. The present invention further provides methods of treating viral-induced skin lesions by administering to a subject in need thereof a therapeutically effective amount of papain and bromelain.... Agent: Edwards Angell Palmer & Dodge LLP

20070275048 - Liposome composition for delivery of a therapeutic agent to eyes: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070275049 - Anti-tumor molecular vacine and method of making thereof: The present invention provides a vaccine which is capable of inhibiting the growth and formation of tumors which can express an endogenous tumor specific protein. Also disclosed are methods of administering the vaccine to a subject bearing a tumor whose formation and growth is inhibited by the vaccine.... Agent: Ben Wang

20070275050 - Method for treating blood coagulation disorders: Provided is a method for treatment of blood coagulation disorders. The method comprises administering to an individual compositions comprising lipidic particles comprising phopatidylcholine, phosphatidylinositol and cholesterol. One or more peptides, polypeptides or proteins involved in the blood coagulation cascade are associated with the lipidic particles.... Agent: Hodgson Russ LLP The Guaranty Building

20070275046 - Noval surfactants and applications thereof: The invention relates to novel surfactant compounds and the use thereof for preparing metastable supramolecular systems or nanoparticles. Said nanoparticles may be used as vectors for active ingredients, in particular therapeutic active ingredients.... Agent: Merchant & Gould PC

20070275047 - Oligonucleotides related to lipid membrane attachments: Oligonucleotide structures are provided that are capable of forming more stable bonds to a lipid membrane and thereby generate an improved control of the process whereby oligonucleotide linkers are introduced to lipid membranes. Methods of forming lipid membrane oligonucleotide attachments are provided including lipid vesicles. The oligonucleotides typically comprise at... Agent: Dinsmore & Shohl, LLP

20070275053 - Anti-stick formula delivered by spray process to facilitate swallowing of solid object, such as pill, tablet capsule or caplet.: An oral delivery method and composition that will facilitate the swallowing of any object such as a pill, tablet, capsule or caplet in a fast, easy, untroubled manner so as to markedly decrease the risk of the pill, caplet, capsule or tablet lodging or sticking in the mouth or the... Agent: Luise Anneliese Lenk

20070275052 - Pharmaceutical compositions containing sterol inhibitors: Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.... Agent: M. Carmen & Associates, PLLC

20070275051 - Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275055 - Compositions capable of facilitating penetration across a biological barrier: This invention relates to novel pharmaceutical compositions mixing one or more effectors (anionic impermeable molecules) with a counter ion to the effector (a liquid forming cation). The invention also relates to methods of treating or preventing diseases by administering pharmaceutical compositions to affected subjects.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275054 - Novel composition and use: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275056 - Method for treating minor aphthous ulcers: A method for treating recurrent minor aphthous ulcers is provided in which a sufferer is treated with a combination therapy of Vitamin B6 and B12 compounds. The treatment is done orally and the treatment minimizes the duration and pain of the sore, as well as increasing the period of time... Agent: Weiss & Moy PC

20070275057 - Formulation and process for the preparation of modafinil: The present invention provides pharmaceutical tablets comprising modafinil particles, processes for preparing such pharmaceutical tablets, and methods of treating a disease or disorder using the pharmaceutical tablet of the invention. In particular, the pharmaceutical tablet of the invention comprises modafinil particles and one or more pharmaceutically acceptable excipients, wherein the... Agent: Sutherland Asbill & Brennan LLP

20070275059 - Flashmelt oral dosage formulation: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275058 - Tablet quickly disintegrating in oral cavity: The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness compared to rapid disintegrating tablets of the prior art. The above objective is solved by a composition in which the inorganic excipient and the disintegrating agent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070275061 - Pharmaceutical compositions and formulations of metformin extended release tablets: The present invention relates to a metformin extended release tablet, particularly to a metformin extended release tablet comprising metformin, which is effective in treating non-insulin dependent diabetes mellitus, as active ingredient, and a matrix in which hydrophilic polymers and hydrophobic materials are mixed at a specific proportion. The hydrophilic polymers... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070275062 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation... Agent: Jones Day

20070275065 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation... Agent: Jones Day

20070275060 - Extended release solid pharmaceutical composition containing carbidopa and levodopa: The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a... Agent: Innovar, LLC

20070275064 - Solid tablets composition rapidly dissolvable in water or watery liquids and used for body, skin, hair and oral hygiene and desinfection: Compositions of solid tablets of quick dissolution in water or aqueous liquids for body or mouth cleansing, skin and hair treatment, and disinfection, wherein said tablet composition comprises from 75% to 92% of at least one disintegrating agent, from 0.5% to 9% of at least one surfactant and from 0.5%... Agent: Fitch Even Tabin And Flannery

20070275063 - Sustained release pharmaceutical compositions and methods of treatment using the same: A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof, of an effective non-toxic amount of an insulin sensitiser so as to provide a plasma concentration of the insulin sensitiser... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275066 - Sustained release drug delivery system composed of water insoluble polymer: The present invention relates to a sustained release drug delivery system composed of a water insoluble polymer, and more particularly, to a sustained release drug delivery system comprising: a crystalline core material; an active ingredient layer which is formed on an outer surface of the crystalline core material and comprises... Agent: The Webb Law Firm, P.C.

20070275067 - Compression coated tablet comprising sumatriptan: The present invention provides a pharmaceutical composition for oral administration, comprising a core of active ingredient and an outer non-active layer formed on the core by application of pressure.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070275068 - Controlled release delivery system for bio-active agents: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range... Agent: Clark & Elbing LLP

20070275070 - Barrier film-forming germicidal composition for controlling mastitis: A long-lasting persistent, uniform film-forming skin protecting germicidal composition provides a long-lasting persistent barrier film when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis. A barrier film-forming agent is selected from the modified or hydrolyzed polysaccharides, particularly a hydrolyzed or modified... Agent: Lathrop & Gage Lc

20070275069 - Hydrophobic biomolecular structure: The present invention relates to a new hydrophobe biomolecular structure, which is compacted due to the passing of the structure over its point of collapse, a method for the preparation of the structure and use of the new structure for the manufacture of a medicament.... Agent: Young & Thompson

20070275072 - Butyl lactate emulsions for the precipitation of water-insoluble drug nanoparticles: Emulsions for use in precipitating water-insoluble drug nanoparticles. The continuous phase of the emulsions include water and an external surfactant. The discontinuous phase of the emulsions include butyl lactate, a co-solvent, an internal surfactant and a water-insoluble drug that is solubilized in the discontinuous phase. The emulsions allow for the... Agent: Rankin, Hill, Porter & Clark, LLP

20070275073 - Clay-based hemostatic agents and devices for the delivery thereof: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate.... Agent: Michaud-duffy Group LLP

20070275076 - Method for the production of porous particles: The present invention provides a method for the production of porous particles that involves extracting an organic solvent from a water-in-oil-in-water emulsion. In accordance with the method of the invention, a first aqueous solution including a porosity-promoting agent is emulsified into an organic solution including a therapeutic constituent and, optionally,... Agent: Rankin, Hill, Porter & Clark, LLP

20070275077 - Wound compress: A wound compress may include a sealed, fluid permeable, fenestrated pouch, and a quantity of particles inside the pouch, each particles having a smallest linear dimension larger than the largest linear dimension of the pouch fenestrations. A wound compress kit may include a wound compress and an overwrap. A method... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070275074 - Controlled agglomeration: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low... Agent: Edwards Angell Palmer & Dodge LLP

20070275075 - Ezetimibe compositions: Provided are ezetimibe compositions with improved solubility and increased bioavailability, methods of their preparation, and method of treatment using the same. An ezetimibe composition may be prepared, for example, by co-milling ezetimibe with at least one hydrophilic excipient.... Agent: Kenyon & Kenyon LLP

20070275071 - Use of microparticles for antigen delivery: The invention relates to microparticles that may be used for antigen delivery and vaccine immunization strategies. The invention in particular relates to microparticles that are useful in the prophylaxis and treatment of human immunodeficiency virus (HIV) infections.... Agent: Clark & Elbing LLP

20070275079 - Antigen-containing microspheres for the treatment of allergies: Microspheres containing antigens for allergy therapy, the microspheres having a binding constant of 1×104 M−1 toward a specific carbohydrate residue of intestinal and/or nasal epithelial cells.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070275078 - Microcapsules for the administration of active ingredients: The present invention relates to microcapsules for the administration of active ingredients, consisting of a core comprising one or more active ingredients, a surfactant and at least one wax or at least one fat, or a mixture of at least one wax and at least one fat, and of a... Agent: Merchant & Gould PC

20070275081 - Aqueous dispersion and its use: The invention relates to a dispersion comprising particles of at least one active substance dispersed in an aqueous solution of a modified starch, wherein said aqueous solution has a pH value in the range 5 to 10, as well as its use. The invention further relates to a process of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275080 - Polymer-based microstructures: The present invention relates to the fields of controlled release of drugs, proteins, nucleic acids, and other pharmaceuticals. It also relates to delivery systems for these agents and other compounds. The invention also relates to stable encapsulation of cells and molecules. The invention provides a population of microstructures comprising a... Agent: Darby & Darby P.C.

20070275082 - Preparation method for sustained release microspheres using a dual-feed nozzle: Disclosed is a method of preparing sustained release microspheres by spray-drying liquids with different compositions for preparation the sustained release microspheres through an ultrasonic dual-feed nozzle. Unlike conventional methods of preparing sustained release microspheres by spray-drying a single liquid containing a biodegradable polymer, a drug, an additive and a solvent... Agent: Medlen & Carroll, LLP

20070275083 - Detection, isolation and uses of renalase (monoamine oxidase c): The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070275085 - Compositions and methods for the cure of hiv / aids: A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection is disclosed. The composition comprises effective amounts of: components obtained from Neem (Azadirachta Indica); and a protein supplement. This composition can be produced by: contacting powdered Neem with water to allow said water to extract components from... Agent: Rajesh Radhakrishnan

20070275084 - Compositions and methods for the treatment of skin damage: The present invention provides methods and compositions for use in cosmetic and dermatological formulations. In various embodiments of the present invention, compositions comprising beta-alanyl-L-histidine (carnosine) or derivatives or analogs thereof and basic milk factor (BMF) for prophylaxis and treatment of aged or photodamaged, or damaged, as in wounded or disrupted,... Agent: Christie, Parker & Hale, LLP

20070275086 - Use of increased molecular-weight hirudin as an anticoagulant in extracorporeal kidney replace therapy: The invention relates to the use of increased-molecular-weight hirudin for the manufacture of an anticoagulant for extracorporeal renal replacement therapy which does not induce an autoimmune disease and which does not cross react with autoimmune antibodies. In particular, the use according to the invention does not induce type II thrombocytopenia... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275087 - Natural composition based on chilean monofloral honey extract from native vegetable species for bacterial infection control in vegetables at all: Natural composition for controlling bacterial infections in potatoes, lettuce, vegetables, cores and flowers in general comprising extracts from monofloral honey flavonoids and/or phenols that act independently as controller of various bacterial infections.... Agent: Millen, White, Zelano & Branigan, P.C.

20070275088 -